CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types 16 and 18.
CERVARIX® is indicated for the following:
CERVARIX® is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies] :
- cervical cancer,
- cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and
- cervical intraepithelial neoplasia (CIN) grade 1.
CERVARIX is approved for use in females 10 through 25 years of age.
Limitations of Use and Effectiveness
CERVARIX does not provide protection against disease due to all HPV types [see Clinical Studies].
CERVARIX has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a woman has previously been exposed through sexual activity [see Clinical Studies].
Females should continue to adhere to recommended cervical cancer screening procedures [see Patient Counseling Information].
Vaccination with CERVARIX may not result in protection in all vaccine recipients.
Media Articles Related to Cervarix (Human Papillomavirus Vaccine)
Physicians Blamed for Low HPV Vaccination Rates
Source: Medscape Pediatrics Headlines [2015.07.30]
Insufficient recommendations by clinicians is the 'primary roadblock' to improving vaccination against HPV, the director of the CDC's National Center for Immunization and Respiratory Diseases said.
Medscape Medical News
Vaccination rates in older adults fall short of targets
Source: Flu / Cold / SARS News From Medical News Today [2015.07.30]
New white paper from Alliance for Aging Research offers recommendations for improvementThe nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention...
Vaccination Schedule for Adults and Adolescents
Source: MedicineNet Chickenpox (Varicella) Specialty [2015.07.07]
Title: Vaccination Schedule for Adults and Adolescents
Category: Procedures and Tests
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/7/2015 12:00:00 AM
HPV Vaccination Tied to Drop in Precancerous Cervical Lesions in U.S.
Source: MedicineNet Cervical Cancer Specialty [2015.06.22]
Title: HPV Vaccination Tied to Drop in Precancerous Cervical Lesions in U.S.
Category: Health News
Created: 6/22/2015 12:00:00 AM
Last Editorial Review: 6/22/2015 12:00:00 AM
Widespread Vaccination Fights Serious Stomach Infection in Kids: CDC
Source: MedicineNet Rotavirus Specialty [2015.06.10]
Title: Widespread Vaccination Fights Serious Stomach Infection in Kids: CDC
Category: Health News
Created: 6/9/2015 12:00:00 AM
Last Editorial Review: 6/10/2015 12:00:00 AM
Published Studies Related to Cervarix (Human Papillomavirus Vaccine)
Impact of malaria and helminth infections on immunogenicity of the human
papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania. 
infections on the immunogenicity of the bivalent HPV-16/18 vaccine... CONCLUSIONS: The data show high HPV immunogenicity regardless of the presence of
A randomized, observer-blinded immunogenicity trial of Cervarix(Â®) and
Gardasil(Â®) Human Papillomavirus vaccines in 12-15 year old girls. 
CONCLUSIONS: These data demonstrate for the first time that cross-neutralizing
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine
(GARDASIL) in Japanese women aged 18-26Â years. 
A randomized double-blind placebo-controlled phase II trial was conducted to
evaluate the efficacy of a prophylactic quadrivalent vaccine targeting the human
papillomavirus (HPV) types most frequently associated with cervical cancer (types
16/18) and genital warts (types 6/11) in Japanese women aged 18-26Â years...
Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine:
a randomized trial in 10-25-year-old HIV-Seronegative African girls and young
have an important public health impact... CONCLUSIONS: The HPV-16/18 AS04-adjuvanted vaccine was highly immunogenic and had
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following
vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle
The exploratory immunogenicity objective of this analysis was to characterize the
titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both
peripartum maternal blood and the cord blood of infants born to women who
received blinded therapy.
Clinical Trials Related to Cervarix (Human Papillomavirus Vaccine)
Drug Use Investigation of CervarixÂ® [Not yet recruiting]
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada [Recruiting]
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and
other pregnancy outcomes, in an Exposed vaccinated cohort, i. e. women with last menstrual
period between 30 days before and 90 days after any dose of CERVARIX, when compared to a
Non-exposed vaccinated cohort, i. e. women with last menstrual period between 120 days and 18
months after the last CERVARIX or GARDASIL dose.
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls [Recruiting]
This is a phase IV study to evaluate the body's immune response of participants to the
Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with
increased risk of cervical cancer.
Post-marketing Safety Study of Autoimmune Diseases Following CervarixÂ® Vaccination [Recruiting]
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases
(AIDs) following females who have received at the least the first dose of CervarixÂ® as part
of their routine health care.
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females [Not yet recruiting]
Infection with human papillomavirus (HPV) has been clearly established as the central cause
of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety
and immunogenicity of Cervarixâ„˘ in HIV infected females aged 15 to 25 years as compared to
Merck's HPV vaccine (GardasilÂ®). For comparative purposes, a group of HIV negative females
will also be evaluated. All subjects will receive the HPV vaccine (either Cervarixâ„˘ or
GardasilÂ®) according to a three-dose schedule (Day 0, Week 6, Month 6).
The protocol posting has been updated following Protocol update in April 2010. The section
impacted is eligibility criteria.